Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema

Phase 2 Recruiting 28 enrolled Kiora Pharmaceuticals, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, open label study to assess the safety, tolerability, and efficacy of KIO-104 administered by IVT injection to the study eye of eligible participants with macular edema.

Timeline

Start: 2025-05-01
Primary completion: 2026-11
Completion: 2026-12

Publications

Background Thurau S, Deuter CME, Heiligenhaus A, Pleyer U, Van Calster J, Barisani-Asenbauer T, Obermayr F, Sperl S, Seda-Zehetner R, Wildner G. A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis - A phase I clinical trial. Front Med (Lausanne). 2022 Oct 17;9:1023224. doi: 10.3389/fmed.2022.1023224. eCollection 2022.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KIO-100	Small molecule	—	Intravitreal

Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema

Summary

Timeline

Publications

Drugs

Indications